Jeffrey Nau, PhD
President & CEO, Oyster Point Pharma
Jeff has built his career on developing novel, innovative therapies for diseases of the eye, with over 15 years of experience working with biotechnology, pharmaceutical, and medical device companies. Most recently, he was VP, Clinical and Medical Affairs, at Ophthotech. Prior to that, he was a Medical Science Director at Genentech working on the development of Lucentis®, a transformative drug for retinal diseases. Jeff has raised more than $250 million in equity for Oyster Point Pharma and start-ups such as Genaera Corporation, Acuity Pharmaceuticals, and NeoVista, Inc. He has numerous patents and peer-reviewed publications. Jeff holds a Master’s in Medical Science and a Ph.D. in Public Health and Epidemiology.